Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus C

Ivor Benjamin, MD
OncoLink Assistant Editor
Ultima Vez Modificado: 21 de mayo del 2000

Translation for this article does not exist